ANTH
Anthera Pharmaceuticals, Orexigen Therapuetics, VEON, and New Gold all posted new 52-week lows Monday.
Published:
Last Updated:
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) saw its shares get absolutely crushed in Monday’s session following missed results in a late-stage study. Specifically, the company said that Sollpura...
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Capital One, Domino's, Home Depot, Mosaic, Regenron, Six Flags, U.S. Steel and Walmart.
Published:
Last Updated:
With the passage of tax reform looking almost certain, and with companies continuing to prove that all-time highs in the market will not hurt spending cash on share buybacks, the continuation of...
Published:
Last Updated:
Guess, Anthera Pharmaceuticals, Walter Investment Managemen, and Rentech all posted new 52-week lows Thursday.
Published:
Last Updated:
Valeant, J.C. Penney, Frontier Communications, and Anthera Pharmaceuticals all posted new 52-week lows Tuesday.
Published:
Last Updated:
December 30, 2016: Here are four stocks trading with relatively heavy volume among 66 equities making new 52-week lows in Friday’s session. On the NYSE, decliners led advancers by about 3 to 2...
Published:
Last Updated:
Thursday’s top analyst upgrades, downgrades and initiations include Biogen, Comerica, Deere, NVIDIA and Twenty-First Century Fox.
Published:
Last Updated:
December 28, 2016: Here are four stocks trading with relatively heavy volume among 59 equities making new 52-week lows in Wednesday’s session. On the NYSE, decliners led advancers by nearly 3...
Published:
Last Updated:
The U.S. presidential election is now over and markets have seemingly recovered to just below their highs but there are still some laggards.
Published:
Last Updated:
Shares of Anthera Pharmaceuticals lost roughly one-third of their value on Thursday after the company gave an update on its late-stage Lupus clinical trial.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
Published:
Last Updated:
On Tuesday, a few biotech companies made substantial runs, either up and down, due to the results of FDA approvals, failed or passed trials and even earnings results.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday, February 19, include Applied Materials, Duke Energy, Entergy, Salesforce,com and SunEdison.
Published:
Last Updated: